ERBB2 and infection: (ii) All recombinants were retargeted to HER2, as inferred by the infection of J-HER2 and SK-OV-3 cells and by inhibition of infection by trastuzumab, the monoclonal antibody (MAb) to HER2 from which the scFv employed for retargeting was derived (44).